33 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Benzo[b]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists.
Korea Research Institute of Chemical Technology
Urotensin II((4-11)) Azasulfuryl Peptides: Synthesis and Biological Activity.
Universit£
Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.
University of Naples&Quot;Federico Ii&Quot
Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.
Korea Research Institute of Chemical Technology
Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists.
Universit£
Deconstruction of sulfonamide inhibitors of the urotensin receptor (UT) and design and synthesis of benzylamine and benzylsulfone antagonists.
Boehringer Ingelheim Pharmaceuticals
Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.
Glaxosmithkline
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.
National Institute of Neuroscienc
New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
University of Naples Federico Ii
N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists.
Glaxosmithkline
Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist.
University of Rouen
Identification of new agonists of urotensin-II from a cyclic peptide library.
Prism Bio. Lab.
Development of potent and selective small-molecule human Urotensin-II antagonists.
Glaxosmithkline
Urotensin-II receptor modulators as potential drugs.
Johnson & Johnson Pharmaceutical Research & Development
Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.
Johnson & Johnson Pharmaceutical Research & Development
Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.
Glaxosmithkline
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.
Glaxosmithkline
Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment.
Johnson & Johnson Pharmaceutical Research & Development
Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.
Università
Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist.
Charit£-Universit£Tsmedizin Berlin
Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.
Aventis Pharma Germany
Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action.
Universit£
Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.
University of Naples "Federico Ii
Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists.
Korea Research Institute of Chemical Technology
Design, parallel synthesis and SAR of novel urotensin II receptor agonists.
G£Teborg University
Novel potent and efficacious nonpeptidic urotensin II receptor agonists.
G£Teborg University
Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).
Acadia Pharmaceuticals
A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.
University of Naples Federico Ii
Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue.
Universit£
Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics.
Universit£